CD40 Ligand antibody (AA 108-261)

Catalog No. ABIN5692812

This Rabbit Polyclonal antibody specifically detects CD40 Ligand in WB and ELISA. It exhibits reactivity toward Human.

Quick Overview for CD40 Ligand antibody (AA 108-261) (ABIN5692812)

Target: CD40 Ligand (CD40LG)

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This CD40 Ligand antibody is un-conjugated

Application: Western Blotting (WB), ELISA

Product Details anti-CD40 Ligand Antibody

Binding Specificity: AA 108-261

Purpose: Anti-CD40L/CD40LG Antibody Picoband®

Cross-Reactivity (Details): No cross-reactivity with other proteins.

Characteristics: Anti-CD40L/CD40LG Antibody Picoband® (ABIN5692812). Tested in ELISA, WB applications. This antibody reacts with Human. The brand Picoband indicates this is a premium antibody that guarantees superior quality, high affinity, and strong signals with minimal background in Western blot applications. Only our best-performing antibodies are designated as Picoband, ensuring unmatched performance.

Immunogen: E. coli-derived human CD40L recombinant protein (Position: E108-L261).

Isotype: IgG

Application Details

Application Notes: Western blot, 0.1-0.5 μg/mL
ELISA, 0.1-0.5 μg/mL
1.Allen,R.C.,Armitage,R.J.,Conley,M.E.,Rosenblatt,H.,Jenkins,N.A.,Copeland,N.G.,Bedell,M.A.,Edelhoff,S.,Disteche,C.M.,Simoneaux,D.K.,Fanslow,W.C.,Belmont,J.,Spriggs,M.K.:CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome. Science 259: 990-993, 1993. 2.Cipollone,F.,Ferri,C.,Desideri,G.,Paloscia,L.,Materazzo,G.,Mascellanti,M.,Fazia,M.,Iezzi,A.,Cuccurullo,C.,Pini,B.,Bucci,M.,Santucci,A.,Cuccurullo,F.,Mezzetti,A.:Preprocedural level of soluble CD40L is predictive of enhanced inflammatory response and restenosis after coronary angioplasty. Circulation 108: 2776-2782, 2003.

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: Add 0.2 mL of distilled water will yield a concentration of 500 μg/mL.

Concentration: 500 μg/mL

Buffer: Each vial contains 4 mg Trehalose, 0.9 mg NaCl, 0.2 mg Na₂HPO₄, 0.05 mg NaN₃.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Store at -20°C for one year from date of receipt. After reconstitution, at 4°C for one month.
It can also be aliquotted and stored frozen at -20°C for six months. Avoid repeated freeze-thaw cycles.

Target Details for CD40 Ligand

Target: CD40 Ligand (CD40LG)

Alternative Name: CD40LG

Background:

Synonyms: CD40 ligand, CD40-L, T-cell antigen Gp39, TNF-related activation protein, TRAP, Tumor necrosis factor ligand superfamily member 5, CD154, CD40 ligand, membrane form, CD40 ligand, soluble form, CD40LG, CD40L, TNFSF5, TRAP

Tissue Specificity: Specifically expressed on activated CD4+ T- lymphocytes.

Background: CD40 ligand (CD40L) is a type II membrane protein of 261 amino acids on activated T cells that induces B cell proliferation and immunoglobulin secretion. It has homology with tumour necrosis factor-alpha and -beta, and has important functions in B-cell activation and differentiation. Human CD40L with 5 exons, is mapped to the proximal region of the mouse X chromosome on Xq26.3-27.1, and can be detected on T cells but is absent from B cells and monocytes. Since CD40L is expressed on platelets and released from them on activation, its predictive value as a marker for clinical outcome and the therapeutic effect of inhibition of glycoprotein IIb /IIIa receptor in patients with acute coronary syndromes was investigated. The soluble CD40L may be involved in the process of restenosis and that it exerts its effect by triggering a complex group of inflammatory reactions on endothelial and mononuclear cells.CD40L plays a central role in the pathophysiology of acute coronary syndromes, and has a role in the pathogenesis of coronary artery lesions.

Molecular Weight: 19 kDa

Gene ID: 959

UniProt: P29965

Pathways: NF-kappaB Signaling, Production of Molecular Mediator of Immune Response, Cancer Immune Checkpoints